hotspot
Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.
The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.
advertisement
“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Moderna hits safety problems in bold bid to reinvent medicine
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat
